ANAB Insider Trading Activity and SEC Form 4 Filings
ANAB insider trading summary
Over the past 12 months, insiders at Anaptysbio, Inc (ANAB) reported 27 sales worth $7.1M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $7.1M.
Latest ANAB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Hollings Renton | Insider | Sell | $249K (5,000 @ $49.87) |
| Mar 30, 2026 | John P. Schmid | Insider | Sell | $702K (12,596 @ $55.71) |
| Mar 30, 2026 | John P. Schmid | Insider | Sell | $30K (522 @ $57.40) |
| Mar 30, 2026 | John P. Schmid | Insider | Sell | $427K (7,527 @ $56.70) |
| Jan 15, 2026 | Magda Marquet | Insider | Sell | $84K (1,710 @ $48.85) |
| Jan 15, 2026 | Magda Marquet | Insider | Sell | $447K (9,290 @ $48.12) |
| Jan 7, 2026 | Daniel Faga | President, CEO | Sell | $415K (9,202 @ $45.11) |
| Jan 7, 2026 | Paul F. Lizzul | Chief Medical Officer | Sell | $101K (2,235 @ $45.11) |
| Jan 7, 2026 | Dennis Mulroy | Chief Financial Officer | Sell | $86K (1,908 @ $45.11) |
| Jan 7, 2026 | Eric J Loumeau | Chief Legal Officer | Sell | $91K (2,017 @ $45.11) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.